MDMX has emerged as a viable target for cancer therapy, both for its own ability to inhibit p53 and its role in the MDM2/MDMX complex, especially in cancers where amplification of MDMX is more prevalent than MDM2 (Gembarska et al., 2012; Burgess et al., 2016). The gene discussed is MDM2; the disease is cancer.